jagomart
digital resources
picture1_Spreadsheet For Expenses 40772 | Business Net Income Merial (1)


 171x       Filetype XLSX       File size 0.07 MB       Source: www.sanofi.com


File: Spreadsheet For Expenses 40772 | Business Net Income Merial (1)
sheet 1 2016 business net income q1 segment results firstquarter firstquarter 2016 pharmaceuticals vaccines others total group euro million q1 2016 q1 2015 change q1 2016 q1 2015 change q1 ...

icon picture XLSX Filetype Excel XLSX | Posted on 14 Aug 2022 | 3 years ago
Partial file snippet.
Sheet 1: 2016 Business Net Income Q1
Segment results first-quarter




























First-quarter 2016 Pharmaceuticals
Vaccines
Others
Total Group
€ million Q1 2016 Q1 2015 Change
Q1 2016 Q1 2015 Change
Q1 2016 Q1 2015
Q1 2016 Q1 2015 Change
Net sales 7,158 7,455 (4.0%)
625 597 4.7%



7,783 8,052 (3.3%)
Other revenues (1) 54 62 (12.9%)
91 106 (14.2%)



145 168 (13.7%)
Cost of Sales (2,097) (2,190) (4.2%)
(350) (376) (6.9%)



(2,447) (2,566) (4.6%)
As % of net sales (29.3%) (29.4%)

(56.0%) (63.0%)




(31.4%) (31.9%)
Gross Profit 5,115 5,327 (4.0%)
366 327 11.9%



5,481 5,654 (3.1%)
As % of net sales 71.5% 71.5%

58.6% 54.8%




70.4% 70.2%
Research and development expenses (1,108) (1,039) 6.6%
(127) (120) 5.8%



(1,235) (1,159) 6.6%
As % of net sales (15.5%) (13.9%)

(20.3%) (20.1%)




(15.9%) (14.4%)
Selling and general expenses (2,046) (2,094) (2.3%)
(166) (156) 6.4%



(2,212) (2,250) (1.7%)
As % of net sales (28.6%) (28.1%)

(26.6%) (26.1%)




(28.4%) (27.9%)
Other operating income/expenses 107 (28)


1

(14) (40)
93 (67)
Share of profit/loss of associates* and joint ventures 16 32

7 (1)




23 31
Net income attributable to non controlling interests (27) (33)








(27) (33)
Business operating income 2,057 2,165 (5.0%)
80 51 56.9%
(14) (40)
2,123 2,176 (2.4%)
As % of net sales 28.7% 29.0%

12.8% 8.5%




27.3% 27.0%





















Financial income & expenses
(117) (96)






Income tax expenses
(455) (491)






Tax rate**
22.6% 23.6%






Business net income excl. Animal Health business
1,551 1,589 (2.4%)






As % of net sales
19.9% 19.7%





















Business net income of Animal Health business
171 137 24.8%





















Business net income
1,722 1,726 (0.2%)


















Business earnings / share
excluding Animal Health business (in €)***

1.20 1.21 (0.8%)






Business earnings / share (in €)***
1.34 1.32 1.5%















* Net of tax.
** Determined on the basis of Business income before tax, associates and non-controlling interests (excluding Animal Health business).
*** Based on an average number of shares outstanding of 1,288.4 million in the first quarter of 2016 and 1,308.4 million in the first quarter of 2015.
(1) As per a change in accounting presentation, Vaxserve sales of non-Group products are reported in Other revenues from 2016 onwards. Prior period Net sales and Other revenues have been represented accordingly.














Sheet 2: 2016 Business Net Income Q2
Segment results second-quarter 2016




























Second-quarter 2016 Pharmaceuticals
Vaccines
Others
Total Group
€ million Q2 2016 Q2 2015 Change
Q2 2016 Q2 2015 Change
Q2 2016 Q2 2015
Q2 2016 Q2 2015 Change
Net sales 7,346 7,800 (5.8%)
797 777 2.6%



8,143 8,577 (5.1%)
Other revenues (1) 68 67 1.5%
97 118 (17.8%)



165 185 (10.8%)
Cost of Sales (2,046) (2,252) (9.1%)
(477) (450) 6.0%



(2,523) (2,702) (6.6%)
As % of net sales (27.9%) (28.9%)

(59.8%) (57.9%)




(31.0%) (31.5%)
Gross Profit 5,368 5,615 (4.4%)
417 445 (6.3%)



5,785 6,060 (4.5%)
As % of net sales 73.1% 72.0%

52.3% 57.3%




71.0% 70.7%
Research and development expenses (1,138) (1,104) 3.1%
(141) (142) (0.7%)



(1,279) (1,246) 2.6%
As % of net sales (15.5%) (14.2%)

(17.7%) (18.3%)




(15.7%) (14.5%)
Selling and general expenses (2,215) (2,216) (0.0%)
(182) (188) (3.2%)



(2,397) (2,404) (0.3%)
As % of net sales (30.2%) (28.4%)

(22.8%) (24.2%)




(29.4%) (28.0%)
Other operating income/expenses 3 (11)

(1) 1

(25) (15)
(23) (25)
Share of profit/loss of associates* and joint ventures 28 29

2 1




30 30
Net income attributable to non controlling interests (23) (29)








(23) (29)
Business operating income 2,023 2,284 (11.4%)
95 117 (18.8%)
(25) (15)
2,093 2,386 (12.3%)
As % of net sales 27.5% 29.3%

11.9% 15.1%




25.7% 27.8%





















Financial income & expenses
(74) (109)






Income tax expenses
(467) (560)






Tax rate**
23.2% 24.6%






Business net income excl. Animal Health business
1,552 1,717 (9.6%)






As % of net sales
19.1% 20.0%





















Business net income of Animal Health business
128 123 4.1%





















Business net income
1,680 1,840 (8.7%)


















Business earnings / share
excluding Animal Health business (in €)***

1.21 1.31 (7.6%)






Business earnings / share (in €)***
1.31 1.41 (7.1%)















* Net of tax.
** Determined on the basis of Business income before tax, associates and non-controlling interests (excluding Animal Health business).
*** Based on an average number of shares outstanding of 1,286.8 million in the second quarter of 2016 and 1,305.9 million in the second quarter of 2015.
(1) As per a change in accounting presentation, Vaxserve sales of non-Group products are reported in Other revenues from 2016 onwards. Prior period Net sales and Other revenues have been represented accordingly.














Sheet 3: 2016 Business Net Income HY
Segment results first-half 2016




























First-Half 2016 Pharmaceuticals
Vaccines
Others
Total Group
€ million H1 2016 H1 2015 Change
H1 2016 H1 2015 Change
H1 2016 H1 2015
H1 2016 H1 2015 Change
Net sales 14,504 15,255 (4.9%)
1,422 1,374 3.5%



15,926 16,629 (4.2%)
Other revenues (1) 122 129 (5.4%)
188 224 (16.1%)



310 353 (12.2%)
Cost of Sales (4,143) (4,442) (6.7%)
(827) (826) 0.1%



(4,970) (5,268) (5.7%)
As % of net sales (28.6%) (29.1%)

(58.2%) (60.1%)




(31.2%) (31.7%)
Gross Profit 10,483 10,942 (4.2%)
783 772 1.4%



11,266 11,714 (3.8%)
As % of net sales 72.3% 71.7%

55.1% 56.2%




70.7% 70.4%
Research and development expenses (2,246) (2,143) 4.8%
(268) (262) 2.3%



(2,514) (2,405) 4.5%
As % of net sales (15.5%) (14.0%)

(18.8%) (19.1%)




(15.8%) (14.5%)
Selling and general expenses (4,261) (4,310) (1.1%)
(348) (344) 1.2%



(4,609) (4,654) (1.0%)
As % of net sales (29.4%) (28.3%)

(24.5%) (25.0%)




(28.9%) (28.0%)
Other operating income/expenses 110 (39)

(1) 2

(39) (55)
70 (92)
Share of profit/loss of associates* and joint ventures 44 61

9





53 61
Net income attributable to non controlling interests (50) (62)








(50) (62)
Business operating income 4,080 4,449 (8.3%)
175 168 4.2%
(39) (55)
4,216 4,562 (7.6%)
As % of net sales 28.1% 29.2%

12.3% 12.2%




26.5% 27.4%





















Financial income & expenses
(191) (205)






Income tax expenses
(922) (1,051)






Tax rate**
22.9% 24.1%






Business net income excl. Animal Health business
3,103 3,306 (6.1%)






As % of net sales
19.5% 19.9%





















Business net income of Animal Health business
299 260 15.0%





















Business net income
3,402 3,566 (4.6%)


















Business earnings / share
excluding Animal Health business (in €)***

2.41 2.53 (4.7%)






Business earnings / share (in €)***
2.64 2.73 (3.3%)















* Net of tax.
** Determined on the basis of Business income before tax, associates and non-controlling interests (excluding Animal Health business).
*** Based on an average number of shares outstanding of 1,287.6 million in the first-half 2016 and 1,307.2 million in the first-half 2015.
(1) As per a change in accounting presentation, Vaxserve sales of non-Group products are reported in Other revenues from 2016 onwards. Prior period Net sales and Other revenues have been represented accordingly.



















































































































































































The words contained in this file might help you see if this file matches what you are looking for:

...Sheet business net income q segment results firstquarter pharmaceuticals vaccines others total group euro million change sales other revenues cost of as gross profit research and development expenses selling general operating incomeexpenses share profitloss associates joint ventures attributable to non controlling interests financial amp tax rate excl animal health earnings excluding in determined on the basis before noncontrolling based an average number shares outstanding first quarter per a accounting presentation vaxserve nongroup products are reported from onwards prior period have been represented accordingly secondquarter second hy firsthalf h...

no reviews yet
Please Login to review.